PDCD1 and non-small cell lung carcinoma: We assessed the capacity of risk score signature to the immunotherapy response in two independent cohorts, namely GSE135222 cohort (patients with advanced non-small cell lung carcinoma treated with anti-PD-1/PD-L1therapy) and IMvigor210 cohort (patients with advanced urothelial cancer treated with anti-PD-L1).